EDITORIAL POLICIES
Journal of Pharmaceutical and Biomedical Sciences (JPBMS) provides quick open access of its content to author /authors and other research scholars for global exchange of knowledge and promotion of research work/activities.
Conflicts of interest and financial disclosures
A conflict of interest may exist when an author (or the author’s institution or employer) has financial or personal relationships or affiliations that could influence (or bias) the author’s decisions, work, or manuscript.
Each authors are required to disclose any potential conflicts of interest, including specific financial interests and relationships and affiliations (other than those affiliations listed in the title page of the manuscript) relevant to the subject of their manuscript. For all accepted manuscripts, each author must declare such conflicts of interest before the manuscript will published. Author without a conflict of interest should include a statement that no such conflicts exist.
All such disclosures must be listed in the Acknowledgment section at the end of the manuscript. .Failure to include this information in the manuscript may delay evaluation and review of the manuscript.
Decisions about whether such information provided by authors should be published, and thereby disclosed to readers, are usually straightforward. Although editors are willing to discuss disclosure of specific conflicts of interest with authors, Journal of Pharmaceutical and Biomedical Sciences(JPBMS) policy is one of complete disclosure of all potential conflicts of interest, including specific financial interests and relationships and affiliations (other than those affiliations listed in the title page of the manuscript) relevant to the subject of their manuscript. The policy requesting disclosure of conflicts of interest applies for all manuscript submissions, including letters to the editor and book reviews. If an author’s disclosure of potential conflicts of interest is determined to be inaccurate or incomplete after publication, a correction will be published to rectify the original published disclosure statement, and additional action may be taken as necessary.
Funding / Support and Role of sponsor
All the financial and material support for research work should be described clearly in an Acknowledgment section of the manuscript. The role of the funding organization/ agency or sponsor in research work should be specified: “design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.”
Data access and responsibility
Regardless of funding source for any manuscript containing original data, one named author ( likely principal investigator) who is independent of any commercial funding or sponsor must indicate that he or she “had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis”. This exact statement should be included in the Acknowledgment section at the end of the manuscript. Modified statements or generic statements indicating that all authors had such access are not acceptable.
For industry-sponsored studies, an analysis of the data (based on the entire raw data set and evaluation of the study protocol, and pre-specified plan for data analysis) must be conducted by an independent statistician at an academic institution, rather than by statisticians employed by the sponsor or by a commercial contract research organization. Details of this independent statistical analysis, the name and institutional affiliation of the independent statistician, and whether compensation or funding was received for conducting the analyses should be reported in the Acknowledgment section of the manuscript. The results of this independent statistical analysis should be the results reported in the manuscript.
Acknowledgment section
The “Acknowledgment section” is the general term for the list of contributions, credits, and other information included at the end of the text of a manuscript but before the references. The Acknowledgment section includes authors’ contributions; information on author access to data; disclosure of potential conflicts of interest, including financial interests and relationships; sources of funding and support; an explanation of the role of sponsor(s); information on independent statistical analysis (if required); names, degrees, and affiliations of participants in a large study or other group; any important disclaimers; information on previous presentation of the information reported in the manuscript; listing of supplemental material; and the contributions, names, degrees, affiliations, and indication of compensation received for all persons who have made substantial contributions to the work but who are not authors.
Authors must obtain written permission to include the names of all individuals included in the Acknowledgment section and the corresponding author must confirm that such permission has been obtained in the Authorship Form.
Duplicate / Previous publication or submission
Manuscripts is considered for the publication with the understanding that the information presented in the manuscript has not been published previously in print or electronic format and that the manuscript is not under consideration by another publication or electronic medium. Copies of related or possibly duplicate materials (i.e. those containing substantially similar content or using the same or similar data) that have been previously published or are under consideration elsewhere must be provided at the time of manuscript submission.
Timeliness of data
Research reports submitted to Journal of Pharmaceutical and Biomedical Sciences (JPBMS) should be timely and current and should be based on data collected as recently as possible.Manuscripts based on data from randomized controlled trials should be reported as soon as possible after the trial has ended, ideally within 1 year after follow-up has been completed. For cohort studies, the date of final follow-up should be no more than 3 to 4 years before manuscript submission. Likewise, data used in case-control or cross-sectional studies should have been collected as recently as possible, but no more than 3 to 4 years before manuscript submission. Because manuscripts in which the most recent data have been collected more than 4 years ago ( i.e. prior to 2005) ordinarily will receive lower priority for publication, authors of such manuscripts should provide a detailed explanation of the relevance of the information in light of current knowledge and medical practice.
Survey research
Manuscripts reporting survey data, such as studies involving patients, clinicians, the public, or others, should report data collected as recently as possible, ideally within the past 2 years. Survey studies should have sufficient response rates (generally at least 60%) and appropriate characterization of non-responders to ensure that non-response bias does not threaten the validity of the findings.
Clinical trial registry
Author are requested to registered all clinical trials from India with “Clinical trials registry – India” ( at www.ctri.in ). Outside India Clinical trials conducted may be registered with any other clinical trial registry.
Reporting race / Ethnicity
If race and/or ethnicity is reported, indicate in the Methods section who classified individuals as to race/ethnicity, the classifications, and whether the options were defined by the investigator or the participant. Explain why race and/or ethnicity were assessed in the study.
Ethical approval of studies and informed consent
For all manuscripts reporting data from studies involving human participants or animals, formal review and approval, or formal review and waiver, by an appropriate institutional review board or ethics committee is required .For investigations involving humans, state in the Methods section whatever oral or written informed consent was obtained from the study participants .Editors may request that authors provide documentation of the formal review and recommendation from the institutional review board or ethics committee responsible for oversight of the study.
Embargo policy
All information regarding the content and publication date of accepted manuscripts is strictly confidential. Unauthorized prepublication release of accepted manuscripts may result in the rejection of the paper.
Unauthorized use
Published manuscripts become the permanent property of Journal of Pharmaceutical and Biomedical Sciences (JPBMS) and may not be published elsewhere without written permission. Unauthorized use of the Journal of Pharmaceutical and Biomedical Sciences (JPBMS) name, logo, or any content for commercial purposes or to promote commercial goods and services in any format (including print, video, audio, and digital) is not permitted by Journal of Pharmaceutical and Biomedical Sciences (JPBMS).
Author ship criteria
Authorship credit should be based only on substantial contributions to each of the three components described below:
1.Concept and design of study or acquisition of data or analysis and interpretation of data;
2.Drafting the article or revising it critically for important intellectual content; and
3.Final approval of the version to be published.
These three conditions must be met. Participation solely in the acquisition of funding or the collection of data does not justify authorship. General supervision of the research group is not sufficient for authorship. Each contributor should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. The order of naming the contributors should be based on the relative contribution of the contributor to the study and preparation of the manuscript. Once the manuscript submitted ,the order cannot be changed without written consent of all the contributors.
For a study from in a single institute the number of contributors should not exceed six. For a case-report, images, letter to the editor and review article the number of contributors should not exceed four. A justification should be included, if the number of contributors exceeds these limits.
Only those who have published substantial work in a particular field can write a review article. A short summary of the work completed by the contributor(s) in the field of review should accompany the manuscript. The journal expects the contributors to give post-publication updates on the subject of review. The update should be brief, covering the advances in the field after the publication of article and should be sent as a letter to editor whenever major development occurs in the field.
Each of the author must complete and submit an Authorship Form/copy right form with signed statements on Authorship Responsibility, Criteria, and Contributions; Financial Disclosure and Funding/ Support; and either Copyright Transfer/Publishing Agreement.
Editorial process
Manuscripts will be reviewed for the consideration of publication with the understanding that they have not been published,simultaneously submitted or already accepted for publication elsewhere. , Manuscripts with plagiarism, serious scientific and technical errors, or lack of a significant message will be rejected. Manuscripts received will be duly acknowledged and manuscript number will be mailed to the corresponding author same day or within 72 hours. Manuscripts are sent to two or more referees and the selection of these reviewers/referees is at the sole discretion of the editor, The journal follows a double-blind review process,where neither the author nor the reviewer’s knows their identity of each other. Members of the teams from Editorial board have the right to take final decision on publication after comments from reviewer’s/Referees have been received .The decision of acceptance, rejection or a requirement of modifications to the manuscript will be conveyed to the corresponding author. If modifications required the corresponding author is requested to reply specifically to the each of comments from referee to the editor and submit the revised manuscript .The amnuscript will not be accepted for publication until editor and reviewer’s/referees were satisfied with the manuscript.
Articles accepted would be copy edited for grammar, punctuation, print style, and format. Page proofs will be sent to the corresponding author, with or without corrections must be returned within three days.
The corresponding author (or coauthor designee) will serve on behalf of all coauthors as the primary correspondent with the editorial office during the submission and review process.